HUP0204333A2 - Use of csaids in rhinovirus infection - Google Patents

Use of csaids in rhinovirus infection

Info

Publication number
HUP0204333A2
HUP0204333A2 HU0204333A HUP0204333A HUP0204333A2 HU P0204333 A2 HUP0204333 A2 HU P0204333A2 HU 0204333 A HU0204333 A HU 0204333A HU P0204333 A HUP0204333 A HU P0204333A HU P0204333 A2 HUP0204333 A2 HU P0204333A2
Authority
HU
Hungary
Prior art keywords
virus
csaids
rhinovirus infection
respiratory
csbp
Prior art date
Application number
HU0204333A
Other languages
Hungarian (hu)
Inventor
Susan B Dillon
Sandra D Griego
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP0204333A2 publication Critical patent/HUP0204333A2/en
Publication of HUP0204333A3 publication Critical patent/HUP0204333A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

A találmány CSBP/p38 kináz inhibitoroknak humán rhinovírus (HRV),egyéb enterovírusok, koronavírus, influenzavírus, parainfluenzavírus,légzőszervi syncytialis vírus vagy adenovírus által okozott közönségesmegfázás vagy légzőszervi vírusfertőzés kezelésére, ezen belülmegelőzésére történő alkalmazására vonatkozik. ÓThe invention relates to the use of CSBP/p38 kinase inhibitors for the treatment, including prevention, of the common cold or respiratory virus infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus or adenovirus. HE

HU0204333A 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection HUP0204333A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17
PCT/US2000/025386 WO2001019322A2 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Publications (2)

Publication Number Publication Date
HUP0204333A2 true HUP0204333A2 (en) 2003-05-28
HUP0204333A3 HUP0204333A3 (en) 2004-07-28

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204333A HUP0204333A3 (en) 1999-09-17 2000-09-15 Use of csaids in rhinovirus infection

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US20030181411A1 (en) * 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
AU2002248269A1 (en) * 2000-10-19 2002-08-12 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
CZ20031125A3 (en) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Novel compounds
BR0309009A (en) * 2002-04-05 2005-03-22 Boehringer Ingelheim Pharma Method for the treatment of mucus hypersecretion
WO2004004725A2 (en) * 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
PE20100737A1 (en) 2005-03-25 2010-11-27 Glaxo Group Ltd NEW COMPOUNDS
DK2276505T3 (en) 2008-03-20 2013-11-25 Krister Tano Nose Spray Or Nasal Drops For Treating A Cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP1140083A4 (en) * 1999-01-08 2004-01-02 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
WO2001019322A2 (en) 2001-03-22
EP1223924A4 (en) 2004-07-14
TR200200673T2 (en) 2002-12-23
BR0014041A (en) 2003-07-15
ZA200202060B (en) 2003-05-28
AU7584500A (en) 2001-04-17
HUP0204333A3 (en) 2004-07-28
CZ2002939A3 (en) 2002-11-13
EP1223924A2 (en) 2002-07-24
CO5200855A1 (en) 2002-09-27
PL363116A1 (en) 2004-11-15
CA2385722A1 (en) 2001-03-22
WO2001019322A3 (en) 2001-10-04
KR20020032591A (en) 2002-05-03
NO20021301L (en) 2002-05-16
NO20021301D0 (en) 2002-03-15
JP2003516314A (en) 2003-05-13
AR025691A1 (en) 2002-12-11
IL148329A0 (en) 2002-09-12
CN1382044A (en) 2002-11-27

Similar Documents

Publication Publication Date Title
HUP0204333A2 (en) Use of csaids in rhinovirus infection
NZ515392A (en) Respiratory syncytial virus replication inhibitors
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
NO20076206L (en) Combination of PDE4 inhibitor rumflumilast and a tetrahydrobioterine derivative
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
ATE276244T1 (en) REPLICATION INHIBITORS OF THE RESPIRATORY SYNZYTIAL VIRUS
ATE376828T1 (en) USE OF ROTIGOTINE FOR THE TREATMENT AND PREVENTION OF PARKINSON PLUS SYNDROME
MY148676A (en) Use of imatinib to treat liver disorders and viral infections
DE50109156D1 (en) MEDICINE TO TREAT DISORDERS OF THE TRACHEO BRONCHIAL TRAIN, IN PARTICULAR THE COPD
HUP0301991A2 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
DE60312736D1 (en) 1,2,4-TRIAMINOBENZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
DK1670489T3 (en) Using xenon with hypothermia to treat neonatal asphyxia
EE200300328A (en) Use of IL-18 inhibitors for the treatment and / or prevention of heart disease
ATE410154T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 2,4-DICHLOROBENZYL ALCOHOL AND AMYLMETACRESOL
HUP0401633A2 (en) Use of irbesartan for the preparation of pharmaceutical compositions that are used to prevent or treat pulmonary hypertension
CO5690571A2 (en) SYNERGIC COMBINATION INCLUDING ROFLUMILAS AND (R, R) -FORMOTEROL
DE60305053D1 (en) Pyrimidine derivatives as selective COX-2 inhibitors
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
RS56006B1 (en) Use of il-18 inhibitors for treating or preventing cns injuries
ATE414538T1 (en) TREATMENT TO REDUCE BODY WEIGHT GAIN
HUP0300754A2 (en) Use of il-8 receptor antagonists in the treatment of virus infections
ECSP055715A (en) USE OF PYRIMETHANIL IN RESISTANT PATHOGENS
DE60305018D1 (en) CITALOPRAM FOR THE TREATMENT OF BLOOD HIGH PRESSURE
MX2007004040A (en) Novel use of -sympathomimetics having a 2-imidazoline structure.
UA100552C2 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety and related disorders

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees